4basebio (LSE:4BB) Total Liabilities: £19.44 Mil (As of Dec. 2025)


LSE:4BB 4basebio PLC LSE:4BB
61 GF Score
Price £5.25
GF Value £28.35
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4basebio Total Liabilities?

4basebio LSE:4BB 61 Total Liabilities is £19.44 Mil as of Dec. 2025. GuruFocus rates LSE:4BB with a GF Score™ of 61/100 and a GF Value™ of £28.35 (Possible Value Trap). The stock has 7 warning signs investors should review.

4basebio's Total Liabilities for the quarter that ended in Dec. 2025 was £19.44 Mil.

4basebio's quarterly Total Liabilities declined from Dec. 2024 (£18.35 Mil) to Jun. 2025 (£17.89 Mil) but then increased from Jun. 2025 (£17.89 Mil) to Dec. 2025 (£19.44 Mil).

4basebio's annual Total Liabilities increased from Dec. 2023 (£12.41 Mil) to Dec. 2024 (£18.35 Mil) and increased from Dec. 2024 (£18.35 Mil) to Dec. 2025 (£19.44 Mil).

4basebio Total Liabilities Historical Data

* Premium members only.

The historical data trend for 4basebio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4basebio Total Liabilities Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 3.01 4.57 12.41 18.35 19.44

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.41 17.15 18.35 17.89 19.44
LSE:4BB
61GF Score
4basebio PLC LSE:4BB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4basebio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

4basebio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.828+(16.553+0.056999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.44

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=29.549-10.111
=19.44

4basebio's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.828+(16.553+0.056999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.44

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=29.549-10.111
=19.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of £19.44 Mil mean?
4basebio (LSE:4BB) has a Total Liabilities of £19.44 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for 4basebio and its competitors.
Is 4basebio's Total Liabilities too high?
4basebio's current Total Liabilities is £19.44 Mil. Overall, 4basebio has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Total Liabilities compare to VRTX and REGN?
4basebio's Total Liabilities of £19.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for 4basebio and its competitors. 4basebio's current Total Liabilities is £19.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £28.35, compared to a current price of £5.25 — trading 81.5% below its estimated fair value. The current Total Liabilities is £19.44 Mil. 4basebio's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current Total Liabilities is £19.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4basebio (LSE:4BB) Overvalued in 2026?

Based on GuruFocus' analysis, 4basebio stock appears to be undervalued. The current stock price of £5.25 is trading 81.5% below its estimated GF Value™ of £28.35. GuruFocus considers 4basebio to be Possible Value Trap.

Key valuation signals for LSE:4BB:

  • Total Liabilities: £19.44 Mil
  • GF Value™: £28.35 vs. price of £5.25 (81.5% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4basebio Business Description

Other Exchanges 88Q:Germany
Address 25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
61GF Score

Get the complete analysis for LSE:4BB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£5.25
Price
£28.35
GF Value